Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing
Sinnecker D, Laugwitz KL, Moretti A (2014)
Publication Type: Journal article, Review article
Publication year: 2014
Journal
Book Volume: 143
Pages Range: 246-252
Journal Issue: 2
DOI: 10.1016/j.pharmthera.2014.03.004
Abstract
Induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for cardiovascular research by providing platforms to study the mechanisms of disease pathogenesis that could lead to new therapies or reveal drug sensitivities. In this review, the potential usefulness of iPSC-derived cardiomyocytes in drug development as well as in drug toxicity testing is discussed, with a focus on the achievements that have been already made in this regard. Moreover, the crucial steps that have to be taken before this technology can be broadly used in drug discovery and toxicology assessments are highlighted. © 2014 Elsevier Inc.
Involved external institutions
Germany (DE)How to cite
APA:
Sinnecker, D., Laugwitz, K.-L., & Moretti, A. (2014). Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. Pharmacology & Therapeutics, 143(2), 246-252. https://doi.org/10.1016/j.pharmthera.2014.03.004
MLA:
Sinnecker, Daniel, Karl-Ludwig Laugwitz, and Alessandra Moretti. "Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing." Pharmacology & Therapeutics 143.2 (2014): 246-252.
BibTeX: Download